Sorafenib Improves Survival in Metastatic Differentiated Thyroid Cancer

TOP Highlights From ASCO 2013

Results from the phase 3 DECISION study showed that sorafenib significantly improved progression-free survival for patients with radioactive iodine–differentialted thyroid cancer.

Read the full story: ASCO Daily News

 

Last modified: July 22, 2021